Skip to main content
SpringerLink
Log in

Pancreatic Gland Signs

  • Chapter
  • First Online:
Endocrine Pathophysiology

  • 684 Accesses

Abstract

The pancreas produces multiple hormones involved in fat, glucose, and protein metabolism. The pathophysiologic basis of the physical manifestations of diabetes mellitus and neuroendocrine tumors is discussed. Explore classic terminologies such as carcinoid and carcinoid syndrome, and develop a better understanding of these often confusing terminologies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Karadağ AS, You Y, Danarti R, Al-Khuzaei S, Chen W. Acanthosis nigricans and the metabolic syndrome. Clin Dermatol. 2018;36:48–53.

    PubMed  Google Scholar 

  2. Bustan RS, Wasim D, Yderstræde KB, Bygum A. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state – a systematic review. Dan Med J. 2017;64:A5316.

    PubMed  Google Scholar 

  3. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clin Diabetes. 2015;33:40–8.

    PubMed  PubMed Central  Google Scholar 

  4. Mistry BD, Alavi A, Ali S, Mistry N. A systematic review of the relationship between glycemic control and necrobiosis lipoidica diabeticorum in patients with diabetes mellitus. Int J Dermatol. 2017;56:1319–27.

    CAS  PubMed  Google Scholar 

  5. Gentile S, Strollo F, Ceriello A. Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear? Diabetes Ther. 2016;7:401–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Heinemann L. Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy? J Diabetes Sci Technol. 2010;4:750–3.

    PubMed  PubMed Central  Google Scholar 

  7. Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. J Diabetes Investig. 2018;9:536–43.

    Google Scholar 

  8. Thornsberry LA, English JC. Etiology, diagnosis, and therapeutic management of granuloma annulare: an update. Am J Clin Dermatol. 2013;14:279–90.

    PubMed  Google Scholar 

  9. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.

    PubMed  Google Scholar 

  10. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin N Am. 2004;88:787–835.

    CAS  PubMed  Google Scholar 

  11. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342. https://doi.org/10.3390/ijms19113342.

    Article  CAS  PubMed Central  Google Scholar 

  12. Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Front Endocrinol. 2018;9:20.

    Google Scholar 

  13. Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37–61.

    CAS  PubMed  Google Scholar 

  14. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S14–31.

    Google Scholar 

  15. Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1:226–37.

    PubMed  PubMed Central  Google Scholar 

  16. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878–84.

    PubMed  PubMed Central  Google Scholar 

  17. Weinreich SS, Bosma A, Henneman L, Rigter T, Spruijt CM, Grimbergen AJ, et al. A decade of molecular genetic testing for MODY: a retrospective study of utilization in The Netherlands. Eur J Hum Genet. 2015;23:29–33.

    CAS  PubMed  Google Scholar 

  18. Carlsson S. Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type 2 diabetes. Front Physiol. 2019;10:320.

    PubMed  PubMed Central  Google Scholar 

  19. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Vijayabala GS, Annigeri RG, Sudarshan R. Mucormycosis in a diabetic ketoacidosis patient. Asian Pac J Trop Biomed. 2013;3:830–3.

    PubMed  PubMed Central  Google Scholar 

  21. Schulz C, Moore J, Hassan D, Tamsett E, Smith CF. Addressing the ‘forgotten art of “fundoscopy”: evaluation of a novel teaching ophthalmoscope’. Eye (Lond). 2016;30:375–84.

    CAS  Google Scholar 

  22. Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: an update. Indian J Ophthalmol. 2008;56:179–88.

    PubMed Central  Google Scholar 

  23. Corcóstegui B, Durán S, González-Albarrán MO, Hernández C, Ruiz-Moreno JM, Salvador J, et al. Update on diagnosis and treatment of diabetic retinopathy: a consensus guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). J Ophthalmol. 2017;2017:8234186. https://doi.org/10.1155/2017/8234186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560. https://doi.org/10.1155/2013/343560.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yan L. Redox imbalance stress in diabetes mellitus: role of the polyol pathway. Animal Model Exp Med. 2018;1:7–13.

    PubMed  PubMed Central  Google Scholar 

  26. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4867–74.

    PubMed  Google Scholar 

  27. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244–52.

    PubMed  Google Scholar 

  28. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816. https://doi.org/10.3390/ijms19061816.

    Article  CAS  PubMed Central  Google Scholar 

  29. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. https://doi.org/10.1172/jci.insight.93751.

    Article  PubMed Central  Google Scholar 

  30. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract—pathogenesis. J Ophthalmol. 2010;2010:608751. https://doi.org/10.1155/2010/608751.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Clayton W, Elasy TA. A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Clin Diabetes. 2009;27:52–8.

    Google Scholar 

  32. Pendsey SP. Understanding diabetic foot. Int J Diabetes Dev Ctries. 2010;30:75–9.

    PubMed  PubMed Central  Google Scholar 

  33. Clements RS. Dietary myo-inositol and diabetic neuropathy. Adv Exp Med Biol. 1979;119:287–94.

    PubMed  Google Scholar 

  34. Zychowska M, Rojewska E, Przewlocka B, Mika J. Mechanisms and pharmacology of diabetic neuropathy – experimental and clinical studies. Pharmacol Rep. 2013;65:1601–10.

    CAS  PubMed  Google Scholar 

  35. Xu L, Huang Z, He X, Wan X, Fang D, Li Y. Adverse effect of metformin therapy on serum vitamin B12 and folate: short-term treatment causes disadvantages? Med Hypotheses. 2013;81:149–51.

    CAS  PubMed  Google Scholar 

  36. Esmaeilzadeh S, Gholinezhad-Chari M, Ghadimi R. The effect of metformin treatment on the serum levels of homocysteine, folic acid, and vitamin B12 in patients with polycystic ovary syndrome. J Hum Reprod Sci. 2017;10:95.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101:1754–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. Singap Med J. 2016;57:55–9.

    Google Scholar 

  39. Fonseca VA, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126:141–9.

    CAS  PubMed  Google Scholar 

  40. Akinlade KS, Agbebaku SO, Rahamon SK, Balogun WO. Vitamin B12 levels in patients with type 2 diabetes mellitus on metformin. Ann Ib Postgrad Med. 2015;13:79–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Oyer DS, Saxon D, Shah A. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test. Endocr Pract. 2007;13:5–10.

    PubMed  Google Scholar 

  42. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:S10–6.

    PubMed  PubMed Central  Google Scholar 

  43. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, et al. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol. 2012;11:100.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Xu P-T, Song Z, Zhang W-C, Jiao B, Yu Z-B. Impaired translocation of GLUT4 results in insulin resistance of atrophic soleus muscle. Biomed Res Int. 2015;2015:291987. https://doi.org/10.1155/2015/291987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Atkinson BJ, Griesel BA, King CD, Josey MA, Olson AL. Moderate GLUT4 overexpression improves insulin sensitivity and fasting triglyceridemia in high-fat diet–fed transgenic mice. Diabetes. 2013;62:2249–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Shanik MH, Xu Y, Škrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31:S262–8.

    CAS  PubMed  Google Scholar 

  47. Young J, Morbois-Trabut L, Couzinet B, et al. Type A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes. 2005;54:1873–8.

    CAS  PubMed  Google Scholar 

  48. Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, et al. Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab. 2010;95:3641–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Hong JH, Kim HJ, Park KS, Ku BJ. Paradigm shift in the management of type B insulin resistance. Ann Transl Med. 2018;6(suppl 2):S98. https://doi.org/10.21037/atm.2018.11.21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Nijim Y, Awni Y, Adawi A, Bowirrat A. Classic case report of donohue syndrome (Leprechaunism; OMIM *246200): the impact of consanguineous mating. Medicine (Baltimore). 2016;95:e2710.

    Google Scholar 

  52. Hodson K, Man CD, Smith FE, Thelwall PE, Cobelli C, Robson SC, et al. Mechanism of insulin resistance in normal pregnancy. Horm Metab Res. 2013;45:567–71.

    CAS  PubMed  Google Scholar 

  53. Bathi RJ, Parveen S, Mutalik S, Rao R. Rabson-Mendenhall syndrome: two case reports and a brief review of the literature. Odontology. 2010;98:89–96.

    PubMed  Google Scholar 

  54. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26:19–39.

    PubMed  PubMed Central  Google Scholar 

  55. Jeninga EH, de Vroede M, Hamers N, Breur JMPJ, Verhoeven-Duif NM, Berger R, et al. A patient with congenital generalized Lipodystrophy due to a novel mutation in BSCL2: indications for secondary mitochondrial dysfunction. JIMD Rep. 2011;4:47–54.

    PubMed  PubMed Central  Google Scholar 

  56. Agarwal AK, Barnes RI, Garg A. Genetic basis of congenital generalized lipodystrophy. Int J Obes Relat Metab Disord. 2004;28:336–9.

    CAS  PubMed  Google Scholar 

  57. Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders - treatment options. Endokrynol Pol. 2017;68:334–51.

    CAS  PubMed  Google Scholar 

  58. Castro PG, de León AM, Trancón JG, Martínez PÁ, Álvarez Pérez JA, Fernández Fernández JC, et al. Glucagonoma syndrome: a case report. J Med Case Rep. 2011;5:402.

    PubMed  PubMed Central  Google Scholar 

  59. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? J Thyroid Res. 2011;2011:9. https://doi.org/10.4061/2011/152850.

    Article  CAS  Google Scholar 

  60. Komada H, Hirota Y, So A, Nakamura T, Okuno Y, Fukuoka H, et al. Insulin secretion and insulin sensitivity before and after surgical treatment of pheochromocytoma or paraganglioma. J Clin Endocrinol Metab. 2017;102:3400–5.

    PubMed  Google Scholar 

  61. Olarescu NC, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegaly. Trends Endocrinol Metab. 2016;27:226–37.

    CAS  PubMed  Google Scholar 

  62. Belo SPM, Magalhães ÂC, Freitas P, Carvalho DM. Familial partial lipodystrophy, Dunnigan variety – challenges for patient care during pregnancy: a case report. BMC Res Notes. 2015;8:140.

    PubMed  PubMed Central  Google Scholar 

  63. Bourron O, Vigouroux C, Halbron M, Touati EB, Capel E, Caron-Debarle M, et al. Association of type B Insulin resistance and type 1 diabetes resulting in ketoacidosis. Diabetes Care. 2012;35:e4.

    PubMed  PubMed Central  Google Scholar 

  64. Chen X, Wang H, Wu B, Dong X, Liu B, Chen H, et al. One novel 2.43Kb deletion and one single nucleotide mutation of the INSR gene in a Chinese neonate with Rabson-Mendenhall syndrome. J Clin Res Pediatr Endocrinol. 2018;10:183–7.

    PubMed  PubMed Central  Google Scholar 

  65. Moore MM, Bailey AM, Flannery AH, Baum RA. Treatment of diabetic ketoacidosis with intravenous U-500 insulin in a patient with Rabson-Mendenhall syndrome: a case report. J Pharm Pract. 2017;30:468–75.

    PubMed  Google Scholar 

  66. Ben Abdelaziz R, Ben Chehida A, Azzouz H, Boudabbous H, Lascols O, Ben Turkia H, et al. A novel homozygous missense mutation in the insulin receptor gene results in an atypical presentation of Rabson-Mendenhall syndrome. Eur J Med Genet. 2016;59:16–9.

    PubMed  Google Scholar 

  67. Gupta J, Daniel JM, Vasudevan V. Rabson-Mendenhall syndrome. J Indian Soc Pedodontics Preventive Dent. 2012;30:279.

    CAS  Google Scholar 

  68. Sinnarajah K, Dayasiri MBKC, Dissanayake NDW, Kudagammana ST, Jayaweera AHHM. Rabson Mendenhall syndrome caused by a novel missense mutation. Int J Pediatr Endocrinol. 2016;2016(1):21. https://doi.org/10.1186/s13633-016-0039-1.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Chong YH, Taylor BJ, Wheeler BJ. Renal manifestations of severe Rabson-Mendenhall syndrome: a case report. J Diabetes Metab Disord. 2013;12:7.

    PubMed  PubMed Central  Google Scholar 

  70. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9:25–53.

    PubMed  PubMed Central  Google Scholar 

  71. Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018;217:2273–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Henquin J-C. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells. Diabetes Res Clin Pract. 2011;93(Suppl 1):S27–31.

    CAS  PubMed  Google Scholar 

  73. Skelin Klemen M, Dolenšek J, Slak Rupnik M, Stožer A. The triggering pathway to insulin secretion: functional similarities and differences between the human and the mouse β cells and their translational relevance. Islets. 2017;9:109–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Rorsman P, Braun M. Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol. 2013;75:155–79.

    CAS  PubMed  Google Scholar 

  75. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest. 2011;121:2118–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010;1:36–47.

    PubMed  PubMed Central  Google Scholar 

  77. Satin LS, Butler PC, Ha J, Sherman AS. Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes. Mol Asp Med. 2015;42:61–77.

    CAS  Google Scholar 

  78. Hou JC, Min L, Pessin JE. Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm. 2009;80:473–506.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol. 2018;57:642–5.

    PubMed  Google Scholar 

  80. Huo J, Liu P, Chen X, Wu J, An J, Ren J. Delayed diagnosis of glucagonoma syndrome: a case report. Int J Dermatol. 2016;55:1272–4.

    PubMed  Google Scholar 

  81. Corrias G, Horvat N, Monti S, Basturk O, Lin O, Saba L, et al. Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: a case report. Medicine (Baltimore). 2017;96:e9252.

    Google Scholar 

  82. Tseng H-C, Liu C-T, Ho J-C, Lin S-H. Necrolytic migratory erythema and glucagonoma rising from pancreatic head. Pancreatology. 2013;13:455–7.

    PubMed  Google Scholar 

  83. Albrechtsen NJW, Challis BG, Damjanov I, Jens JH. Do glucagonomas always produce glucagon? Bosn J Basic Med Sci. 2016;16:1–7.

    CAS  PubMed Central  Google Scholar 

  84. Zhang K, Lehner LJ, Praeger D, Baumann G, Knebel F, Quinkler M, et al. Glucagonoma-induced acute heart failure. Endocrinol Diabetes Metab Case Rep. 2014;2014:140061. https://doi.org/10.1530/EDM-14-0061.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Demir OM, Paschou SA, Ellis HC, Fitzpatrick M, Kalogeropoulos AS, Davies A, et al. Reversal of dilated cardiomyopathy after glucagonoma excision. Hormones (Athens). 2015;14:172–3.

    Google Scholar 

  86. John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30:2016–22.

    CAS  PubMed  Google Scholar 

  87. Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018;25:22.

    PubMed  PubMed Central  Google Scholar 

  88. Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.

    PubMed  PubMed Central  Google Scholar 

  89. Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord. 2016;17:373–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol Sci. 2018;39:560–72.

    CAS  PubMed  Google Scholar 

  91. Frazer A, Hensler JG. Chapter 13: serotonin receptors. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic neurochemistry: molecular, cellular, and medical aspects. Philadelphia: Lippincott-Raven; 1999. p. 263–92.

    Google Scholar 

  92. Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. JCO. 2016;35:14–23.

    Google Scholar 

  93. Biçer EN, Öztürk AB, Ozyigit LP, Erus S, Tanju S, Dilege Ş, et al. A case of uncontrolled severe asthma patient with coexisting carcinoid tumor presenting as pneumomediastinum. J Asthma. 2015;52:1095–8.

    PubMed  Google Scholar 

  94. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA. Pulmonary neuroendocrine/carcinoid tumors. Cancer. 2009;115:4434–41.

    PubMed  Google Scholar 

  95. Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart. 2017;103:1488–95.

    CAS  PubMed  Google Scholar 

  96. Savvidou S. Pellagra: a non-eradicated old disease. Clin Pract. 2014;4(1):637. https://doi.org/10.4081/cp.2014.637.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Crook MA. The importance of recognizing pellagra (niacin deficiency) as it still occurs. Nutrition. 2014;30:729–30.

    PubMed  Google Scholar 

  98. Bell HK, Poston GJ, Vora J, Wilson NJE. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152:71–5.

    CAS  PubMed  Google Scholar 

  99. Kleyn CE, Bell H, Postin G, Wilson N. Cutaneous manifestations of the malignant carcinoid syndrome1. J Am Acad Dermatol. 2004;50:P113.

    Google Scholar 

  100. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825. https://doi.org/10.1155/2012/287825.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007;10:123–33.

    PubMed  Google Scholar 

  102. Dierdorf SF. Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol. 2003;16:343–7.

    PubMed  Google Scholar 

  103. Soga J. The term “carcinoid” is a misnomer: the evidence based on local invasion. J Exp Clin Cancer Res. 2009;28:15.

    PubMed  PubMed Central  Google Scholar 

  104. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. Hematol Oncol Stem Cell Ther. 2014;7:109–15.

    PubMed  Google Scholar 

  106. Hagen BM, Bayguinov O, Sanders KM. VIP and PACAP regulate localized Ca2+ transients via cAMP-dependent mechanism. Am J Phys Cell Phys. 2006;291:C375–85.

    CAS  Google Scholar 

  107. Tang B, Yong X, Xie R, Li Q-W, Yang S-M. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol. 2014;44:1023–31.

    CAS  PubMed  Google Scholar 

  108. Fujiya A, Kato M, Shibata T, Sobajima H. VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation. BMJ Case Rep. 2015;2015:bcr2015213016. https://doi.org/10.1136/bcr-2015-213016.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295–330.

    CAS  Google Scholar 

  110. Remme CA, de Groot GH, Schrijver G. Diagnosis and treatment of VIPoma in a female patient. Eur J Gastroenterol Hepatol. 2006;18:93–9.

    PubMed  Google Scholar 

  111. Apodaca-Torrez FR, Triviño M, Lobo EJ, Goldenberg A, Triviño T. Extra-pancreatic vipoma. Arq Bras Cir Dig. 2014;27:222–3.

    PubMed  PubMed Central  Google Scholar 

  112. Da Silva XG. The cells of the islets of Langerhans. J Clin Med. 2018;7(3):54. https://doi.org/10.3390/jcm7030054.

    Article  CAS  Google Scholar 

  113. Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, Delta- and PP-cells. J Histochem Cytochem. 2015;63:575–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Kiriyama Y, Nochi H. Role and cytotoxicity of amylin and protection of pancreatic islet β-cells from amylin cytotoxicity. Cell. 2018;7(8):95. https://doi.org/10.3390/cells7080095.

    Article  CAS  Google Scholar 

  115. Briant L, Salehi A, Vergari E, Zhang Q, Rorsman P. Glucagon secretion from pancreatic α-cells. Ups J Med Sci. 2016;121:113–9.

    PubMed  PubMed Central  Google Scholar 

  116. Iki K, Pour PM. Distribution of pancreatic endocrine cells including IAPP-expressing cells in non-diabetic and type 2 diabetic cases. J Histochem Cytochem. 2007;55:111–8.

    CAS  PubMed  Google Scholar 

  117. Napolitano T, Silvano S, Vieira A, Balaji S, Garrido-Utrilla A, Friano ME, et al. Role of ghrelin in pancreatic development and function. Diabetes Obes Metab. 2018;20(Suppl 2):3–10.

    PubMed  Google Scholar 

  118. Smith JP, Fonkoua LK, Moody TW. The role of gastrin and CCK receptors in pancreatic cancer and other malignancies. Int J Biol Sci. 2016;12:283–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  119. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6:229–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Zhang WD, Liu DR, Wang P, Zhao JG, Wang ZF, Chen L. Clinical treatment of gastrinoma: a case report and review of the literature. Oncol Lett. 2016;11:3433–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Ligiero Braga T, Santos-Oliveira R. PPoma review: epidemiology, aetiopathogenesis, prognosis and treatment. Diseases. 2018;6(1):8. https://doi.org/10.3390/diseases6010008.

    Article  CAS  PubMed Central  Google Scholar 

  122. Williamson J, Thorn C, Spalding D, Williamson R. Pancreatic and peripancreatic somatostatinomas. Ann R Coll Surg Engl. 2011;93:356–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Tsoukalas N, Chatzellis E, Rontogianni D, Alexandraki KI, Boutzios G, Angelousi A, et al. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms). Medicine. 2017;96(16):e6201. https://doi.org/10.1097/MD.0000000000006201.

    Article  PubMed  PubMed Central  Google Scholar 

  124. La Rosa S, Franzi F, Albarello L, Schmitt A, Bernasconi B, Tibiletti MG, et al. Serotonin-producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors. Pancreas. 2011;40:883–95.

    PubMed  Google Scholar 

  125. Oberg K, Casanovas O, Castaño JP, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19:2842–9.

    CAS  PubMed  Google Scholar 

  126. Gaur P, Sceusi EL, Samuel S, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141:1728–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. Dai H, Hong X, Wang X, Lin C, Wu W, Zhao Y. Pancreatic neuroendocrine tumor cancer stem cells: potential novel therapeutic targets? Trans Cancer Res. 2016;5:860–70.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

    Andrea Manni

  2. Sanford Health Clinic, Bemidji, MN, USA

    Akuffo Quarde

Authors
  1. Andrea Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akuffo Quarde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Manni .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manni, A., Quarde, A. (2020). Pancreatic Gland Signs. In: Endocrine Pathophysiology. Springer, Cham. https://doi.org/10.1007/978-3-030-49872-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49872-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-49871-9

  • Online ISBN: 978-3-030-49872-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation